Teaching Adolescents with Type 1 Diabetes Self-compassion (TADS)

Teaching Adolescents with Type 1 Diabetes Self-compassion to Reduce Diabetes Distress: a Randomized Controlled Trial

The purpose of this study is to see if a mindful self-compassion program given virtually can improve emotional distress for youth with type 1 diabetes, compared to routine care as usual.

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes
• Intervention / Treatment: Behavioral: Mindful Self-Compassion Program

Detailed Description

Background: Type 1 diabetes (T1D) is a chronic, life-long condition. Youth with T1D must monitor their blood sugar levels, nutrition, physical activity, and other daily activities. They also need insulin multiple times per day.

Diabetes distress can happen when all the worry, frustration, anger, and burnout make it hard for people with diabetes to take care of themselves and keep up with the daily demands of their condition. Most youth with T1D experience diabetes distress and over one third experience severe diabetes distress.

Self-compassion is a practice that involves acting the same way towards yourself as you would with friends and loved ones, and that you are kind and understanding towards yourself. Since self-compassion is a skill that can be taught, we hypothesize that it could be a strategy to improve mental health issues in youth with T1D, like diabetes distress.

Objectives: The aim of our study is to assess the effectiveness of a mindful self-compassion program on improving the diabetes distress experienced by youth aged 12-17 years with T1D. We will compare if diabetes distress 3 months after enrolment in the study is different among youth that received the mindful self-compassion program versus the ones that did not. We will also assess the effect of the program on anxiety, depression, diabetes-related disordered eating, and suicidal ideation. Finally, we will explore the effect of the program on blood sugar control, and if the effects change over time.

Methods: Our study will be a randomized controlled trial of youth aged 12-17 years, with a diagnosis of T1D. Participants will be recruited from the diabetes clinic at the Children's Hospital of Eastern Ontario (CHEO) and randomized to the mindful self-compassion program or a wait-list control group. The mindful self-compassion program will consist of weekly virtual 1.5-hour sessions/workshops for 8 weeks, led by a trained facilitator. It will cover a variety of self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice. The wait-list group will be offered the mindful self-compassion program once the experimental period of the study is over.

Outcomes in both groups will be assessed at the start of the study, 8-weeks, and at 3-, 6-, and 12- months. Participants showing signs of suicidal ideation or severe depression will be assessed clinically by the study doctor and appropriate follow up actions will be taken.

• Study Type: Interventional
• Enrollment (Actual): 141
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontatrio
    • Ottawa, Ontatrio, Canada, K1H8L1
      • Children's Hospital of Eastern Ontario

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Between 12-17 years of age
• Diagnosed with type 1 diabetes at least 6 months prior to enrollment
• Able to provide informed consent

Exclusion Criteria:

• Unable or unwilling to provide informed consent
• Do not speak English or French with enough fluency to complete all study related tasks
• Presence of an intellectual disability that would preclude participation in the MSC intervention, as assessed by the treating physician
• Lifetime diagnosis of a serious mental illness given by a clinician (e.g., psychotic or bipolar disorders), as these often involve intensive treatments with psychological and/or pharmacologic implications, which may confound our results.
• Presence of acute suicidality at the time of enrollment (if a patient reports suicidality on the baseline questionnaires, a same-day assessment will be conducted to assess for acute suicidality. If present, the patient will receive immediate clinical attention and will no longer be eligible to participate in the study).
• Active participation in another mental health intervention trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mindful Self-Compassion Arm; Participants in this arm will participate in an 8-week virtual mindful self-compassion program.	Behavioral: Mindful Self-Compassion Program; The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
No Intervention: Wait-list Control Arm; Participants in this arm will receive usual clinical care and will have the opportunity to participate in the mindful self-compassion program at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diabetes Distress as measured by the Problem Areas in Diabetes - Teen Version (PAID-T)	Diabetes distress as measured by the PAID-T will be compared in those who complete the MSC program to those in the wait-list control group at 3 months. Scores can range from 26-156, with scores of <70, 70-90, and >90 representing none-to-mild, moderate, and severe diabetes distress, respectively.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anxiety as measured by the Generalized Anxiety 7-item scale (GAD-7)	Anxiety as measured by the GAD-7 will be compared between those who complete the MSC program and those in the wait-list control group at 3 months and at 12 months. The GAD-7 is scored from 0-21, with 0-4, 5-9, 10-14, and 15-21 indicating minimal, mild, moderate, and severe anxiety symptoms respectively.	3 months, 12 months
Depression as measured by the Patient Health Questionnaire (PHQ-9)	Depression as measured by the PHQ-9 in those who complete the MSC program compared to those in the wait-list control group will be assessed at 3 months and at 12 months. PHQ-9 scores range from 0-27, and in adolescents, scores of 0-4, 5-10, 11-14, 15-19, and ≥20 indicate absence of depression, mild depression, moderate depression, moderately severe depression, and severe depression respectively.	3 months, 12 months
Disordered eating as measured by the Diabetes Eating Problem Survey, revised version (DEPS-R)	Disordered eating as measured by the DEPS-R will be compared in those who complete the MSC program and those in the wait-list control group at 3 months and at 12 months. The DEPS-R is scored 0-80, with higher scores indicating more disordered eating behaviors and a score of ≥20 considered a positive screen for disordered eating behaviours.	3 months, 12 months
Suicidal ideation as measured by the Patient Health Questionnaire (PHQ-9)	Suicidal ideation in those who complete the MSC intervention will be compared to those in the wait-list control group at 3 months and at 12 months. Suicidal ideation will be assessed using one question on the PHQ-9, which asks the respondent if they have had thoughts that they would be better off dead, or of hurting themselves in the previous two weeks. This question is scored on a scale of 0 (not at all) to 3 (nearly every day). In line with previous use of the PHQ-9, we will consider any score of >0 to be indicative that suicidal ideation is present.	3 months, 12 months
Diabetes distress as measured by the Problem Areas in Diabetes - Teen version (PAID-T)	Diabetes distress as measured by the PAID-T will be compared in those who complete the MSC program to those in the wait-list control group at 12 months. Scores can range from 26-156, with scores of <70, 70-90, and >90 representing none-to-mild, moderate, and severe diabetes distress, respectively.	12 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Interaction term of time and diabetes distress	We will assess whether the effect of the MSC intervention on diabetes distress, as measured by the Problem Areas In Diabetes - Teen version (PAID-T) changes over time by exploring the interaction of time (i.e., study timepoint) with diabetes distress.	Baseline, 8 weeks, 3 months, 6 months, 12 months
Hemoglobin A1c	HbA1c is a measure of the average blood glucose levels over the previous 3 months and is a routinely followed biochemical marker used to gauge metabolic control in individuals with T1D. We will explore change in HbA1c over the duration of our trial as mental health morbidity has been associated with higher HbA1c levels. A change of more than 0.5% will be considered clinically significant.	Baseline, 12 months
Time in Range	Time in range is a metric that denotes the proportion of time that a person's glucose level is within a desired target range. Continuous glucose monitoring (CGM) devices are required to calculate time in range. Fourteen days of data from CGM provides a good approximation of glucose data; time in range will allow us to evaluate the glucose control at the various study time points.	Baseline, 8 weeks, 3 months, 6 months, 12 months

Collaborators and Investigators

• Sponsor: Children's Hospital of Eastern Ontario
• Collaborators: Juvenile Diabetes Research Foundation; Brain Canada
• Investigators: Principal Investigator: Marie-Eve Robinson, MD, MSc, Children's Hospital of Eastern Ontario

Study record dates

Study Major Dates

• Study Start (Actual): October 4, 2022
• Primary Completion (Actual): March 1, 2023
• Study Completion (Actual): April 1, 2024

Study Registration Dates

• First Submitted: July 12, 2022
• First Submitted That Met QC Criteria: July 14, 2022
• First Posted (Actual): July 19, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 14, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 22/08E

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD will be made available upon reasonable request from other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No